{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T16:49:56Z","timestamp":1776703796314,"version":"3.51.2"},"reference-count":43,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["brachyjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brachytherapy"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.brachy.2015.12.011","type":"journal-article","created":{"date-parts":[[2016,2,28]],"date-time":"2016-02-28T12:55:05Z","timestamp":1456664105000},"page":"288-295","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Predictive factors for urinary toxicity after iodine-125 prostate brachytherapy with or without supplemental external beam radiotherapy"],"prefix":"10.1016","volume":"15","author":[{"given":"Takahisa","family":"Eriguchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsunori","family":"Yorozu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuko","family":"Kuroiwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuto","family":"Yagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiro","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhito","family":"Toya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Hanada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoyuki","family":"Shigematsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.brachy.2015.12.011_bib1","unstructured":"NCCN Guidelines Version 2.2015. Available at: http:\/\/www.nccn.org. Accessed September 21,\u00a02015."},{"key":"10.1016\/j.brachy.2015.12.011_bib2","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.radonc.2013.09.026","article-title":"Long-term results of the Dutch randomized prostate cancer trial: Impact of dose-escalation on local, biochemical, clinical failure, and survival","volume":"110","author":"Heemsbergen","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2015.12.011_bib3","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijrobp.2007.06.054","article-title":"Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer","volume":"70","author":"Kuban","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"Suppl. 7","key":"10.1016\/j.brachy.2015.12.011_bib4","article-title":"ASCENDE-RT*: A multicenter, randomized trial of dose-escalated external beam radiation therapy (EBRT-B) versus low-dose-rate brachytherapy (LDR-B) for men with unfavorable-risk localized prostate cancer","volume":"33","author":"Morris","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.brachy.2015.12.011_bib5","first-page":"975","article-title":"Systematic overview of the evidence for brachytherapy in clinically localized prostate cancer","volume":"164","author":"Crook","year":"2001","journal-title":"CMAJ"},{"key":"10.1016\/j.brachy.2015.12.011_bib6","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0360-3016(03)00210-4","article-title":"Urinary symptom flare following I-125 prostate brachytherapy","volume":"56","author":"Cesaretti","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2015.12.011_bib7","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.ijrobp.2014.06.037","article-title":"Late urinary side effects 10 years after low-dose-rate prostate brachytherapy: Population-based results from a multiphysician practice treating with a standardized protocol and uniform dosimetric goals","volume":"90","author":"Keyes","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2015.12.011_bib8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.juro.2011.09.045","article-title":"Factors influencing urinary symptoms 10 years after permanent prostate seed implantation","volume":"187","author":"Stone","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.brachy.2015.12.011_bib9","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.brachy.2014.06.008","article-title":"Permanent prostate brachytherapy with or without supplemental external beam radiotherapy as practiced in Japan: Outcomes of 1300 patients","volume":"14","author":"Yorozu","year":"2015","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2015.12.011_bib10","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ijrobp.2005.07.981","article-title":"Biologically effective dose values for prostate brachytherapy: Effects on PSA failure and posttreatment biopsy results","volume":"64","author":"Stock","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2015.12.011_bib11","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.brachy.2013.10.005","article-title":"Decline in acute urinary toxicity: A long-term study in 2011 patients with prostate brachytherapy within a provincial institution","volume":"13","author":"Chan","year":"2014","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2015.12.011_bib12","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.brachy.2013.12.001","article-title":"Assessing protection against radiation exposure after prostate (125)I brachytherapy","volume":"13","author":"Hanada","year":"2014","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2015.12.011_bib13","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.urology.2006.01.063","article-title":"Association of neoadjuvant hormonal therapy with adverse health-related quality of life after permanent iodine-125 brachytherapy for localized prostate cancer","volume":"68","author":"Pinkawa","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.brachy.2015.12.011_bib14","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa074311","article-title":"Quality of life and satisfaction with outcome among prostate-cancer survivors","volume":"358","author":"Sanda","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.brachy.2015.12.011_bib15","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/00130404-200405000-00008","article-title":"The impact of prostate volume and neoadjuvant androgen-deprivation therapy on urinary function following prostate brachytherapy","volume":"10","author":"Merrick","year":"2004","journal-title":"Cancer J"},{"key":"10.1016\/j.brachy.2015.12.011_bib16","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0360-3016(01)02658-X","article-title":"Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation","volume":"52","author":"Crook","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2015.12.011_bib17","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.urology.2010.02.051","article-title":"No long-term effects of hormonal therapy preceding brachytherapy on urinary function and health-related quality of life among prostate cancer patients","volume":"76","author":"Evers","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.brachy.2015.12.011_bib18","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S0360-3016(01)02657-8","article-title":"Risk factors for acute urinary retention requiring temporary intermittent catheterization after prostate brachytherapy: A prospective study","volume":"52","author":"Locke","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2015.12.011_bib19","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0360-3016(03)00640-0","article-title":"RTOG 94\u201306: Is the addition of neoadjuvant hormonal therapy to dose-escalated 3D conformal radiation therapy for prostate cancer associated with treatment toxicity?","volume":"57","author":"Valicenti","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2015.12.011_bib20","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.brachy.2007.08.007","article-title":"Androgen deprivation-mediated cytoreduction before interstitial brachytherapy for prostate cancer does not abrogate the elevated risk of urinary morbidity associated with larger initial prostate volume","volume":"6","author":"Petit","year":"2007","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2015.12.011_bib21","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.urology.2007.11.067","article-title":"Does timing of androgen deprivation influence radiation-induced toxicity? A secondary analysis of radiation therapy oncology group protocol 9413","volume":"72","author":"Taussky","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.brachy.2015.12.011_bib22","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1530\/JOE-12-0142","article-title":"Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells","volume":"214","author":"Vignozzi","year":"2012","journal-title":"J Endocrinol"},{"key":"10.1016\/j.brachy.2015.12.011_bib23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11255-014-0845-4","article-title":"The alteration of inflammatory markers and apoptosis on chronic prostatitis induced by estrogen and androgen","volume":"47","author":"Jia","year":"2015","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.brachy.2015.12.011_bib24","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ijrobp.2007.06.067","article-title":"(125)I monotherapy using D90 implant doses of 180 Gy or greater","volume":"70","author":"Kao","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2015.12.011_bib25","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ijrobp.2009.07.1723","article-title":"Biochemical disease-free rate and toxicity for men treated with iodine-125 prostate brachytherapy with d(90) \u2265180 Gy","volume":"78","author":"G\u00f3mez-Iturriaga Pi\u00f1a","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2015.12.011_bib26","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.ijrobp.2014.08.340","article-title":"A dose-response analysis of biochemical control outcomes after (125)I monotherapy for patients with favorable-risk prostate cancer","volume":"90","author":"Shiraishi","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2015.12.011_bib27","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.ijrobp.2008.11.043","article-title":"Urinary symptom flare in 712 125I prostate brachytherapy patients: Long-term follow-up","volume":"75","author":"Keyes","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2015.12.011_bib28","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/00000478-198209000-00006","article-title":"Radiation injury of the normal and neoplastic prostate","volume":"6","author":"Bostwick","year":"1982","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.brachy.2015.12.011_bib29","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/00000478-200302000-00009","article-title":"Atypia in nonneoplastic prostate glands after radiotherapy for prostate cancer: Duration of atypia and relation to type of radiotherapy","volume":"27","author":"Magi-Galluzzi","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.brachy.2015.12.011_bib30","first-page":"107","article-title":"Histopathological changes induced by therapies in the benign prostate and prostate adenocarcinoma","volume":"22","author":"Petraki","year":"2007","journal-title":"Histol Histopathol"},{"key":"10.1016\/j.brachy.2015.12.011_bib31","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1097\/00000478-199909000-00004","article-title":"Histopathologic effects of three-dimensional conformal external beam radiation therapy on benign and malignant prostate tissues","volume":"23","author":"Gaudin","year":"1999","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.brachy.2015.12.011_bib32","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1148\/radiology.175.3.2343132","article-title":"Postirradiation changes in the pelvis: Assessment with MR imaging","volume":"175","author":"Sugimura","year":"1990","journal-title":"Radiology"},{"key":"10.1016\/j.brachy.2015.12.011_bib33","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0360-3016(99)00232-1","article-title":"Efficacy of selective alpha-1 blocker therapy in the treatment of acute urinary symptoms during radiotherapy for localized prostate cancer","volume":"45","author":"Zelefsky","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2015.12.011_bib34","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0090-4295(02)01840-X","article-title":"Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy","volume":"60","author":"Merrick","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.brachy.2015.12.011_bib35","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ijrobp.2004.09.036","article-title":"Prophylactic tamsulosin (Flomax) in patients undergoing prostate 125I brachytherapy for prostate carcinoma: Final report of a double-blind placebo-controlled randomized study","volume":"62","author":"Elshaikh","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2015.12.011_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brachy.2007.12.002","article-title":"Combined brachytherapy with external beam radiotherapy for localized prostate cancer: Reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy","volume":"7","author":"Zelefsky","year":"2008","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2015.12.011_bib37","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0360-3016(01)01811-9","article-title":"The dosimetry of prostate brachytherapy-induced urethral strictures","volume":"52","author":"Merrick","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2015.12.011_bib38","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/S0022-5347(05)00681-6","article-title":"Risk factors for the development of prostate brachytherapy related urethral strictures","volume":"175","author":"Merrick","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.brachy.2015.12.011_bib39","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.radonc.2012.06.001","article-title":"Correlation between prostate brachytherapy-related urethral stricture and peri-apical urethral dosimetry: A matched case-control study","volume":"104","author":"Earley","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2015.12.011_bib40","doi-asserted-by":"crossref","first-page":"e775","DOI":"10.1016\/j.ejrad.2013.09.011","article-title":"MRI findings of radiation-induced changes in the urethra and periurethral tissues after treatment for prostate cancer","volume":"82","author":"Marigliano","year":"2013","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.brachy.2015.12.011_bib41","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ijrobp.2007.12.052","article-title":"Segmental urethral dosimetry and urinary toxicity in patients with no urinary symptoms before permanent prostate brachytherapy","volume":"72","author":"Thomas","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2015.12.011_bib42","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ijrobp.2014.06.031","article-title":"Dose to the bladder neck is the most important predictor for acute and late toxicity after low-dose-rate prostate brachytherapy: Implications for establishing new dose constraints for treatment planning","volume":"90","author":"Hathout","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2015.12.011_bib43","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.ijrobp.2011.06.2013","article-title":"Intensity-modulated radiotherapy causes fewer side effects than three-dimensional conformal radiotherapy when used in combination with brachytherapy for the treatment of prostate cancer","volume":"83","author":"Forsythe","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Brachytherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153847211600012X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153847211600012X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T02:09:21Z","timestamp":1761530961000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153847211600012X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S153847211600012X"],"URL":"https:\/\/doi.org\/10.1016\/j.brachy.2015.12.011","relation":{},"ISSN":["1538-4721"],"issn-type":[{"value":"1538-4721","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictive factors for urinary toxicity after iodine-125 prostate brachytherapy with or without supplemental external beam radiotherapy","name":"articletitle","label":"Article Title"},{"value":"Brachytherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brachy.2015.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}